Physician profile
Marc R Imundo
NPI 1053303073
$1,459.82
in general payments reported to CMS, 2019-2025
15 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $191 · 2021: $350 · 2022: $248 · 2023: $136 · 2024: $135 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $261.81 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $199.76 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $192.42 | 2019-2021 | |
| Oyster Point Pharma, INC. | $151.60 | 2022-2024 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $146.37 | 2019-2025 | Cequa |
| Alcon Vision LLC | $119.92 | 2022-2025 | Simbrinza |
| Bausch & Lomb Americas INC. | $105.77 | 2022-2024 | Miebo, Xiidra |
| Abbvie INC. | $70.57 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $57.38 | 2019 | |
| Kala Pharmaceuticals, INC. | $39.21 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $32.18 | 2020 | |
| Biotissue Holdings INC. | $24.17 | 2023 | |
| Harrow Eye, LLC | $22.33 | 2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $19.55 | 2025 | Xdemvy |
| Akorn Operating Company LLC | $16.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Imundo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.